We have also confirmed that the molecular mechanism underlying BRAF-inhibitor resistance in these three melanoma models is the aberrant re-activation of Ras/RAF/MEK/ERK signaling, which is consistent with clinical data [25]. The gene discussed is MAP2K7; the disease is melanoma.